11/9/2012

An FDA panel on Thursday voted 8-4 to recommend approval of Novo Nordisk's once-daily insulin degludec despite concerns about cardiovascular safety, stating that the drug's benefits outweigh possible risks.

Full Story:
Reuters

Related Summaries